Combretastatin A4 Prodrug : OXiGENE : Angiogenesis inhibitor

Combretastatin A4 Prodrug (OXiGENE)
Describes Combretastatin A4 Prodrug, an angiogenesis inhibitor and anti-tumor vascular targeting agent, and how it works. See also the OXiGENE press release on the Phase IB trial. [2/02]

Combretastatin (EurekAlert)
Press release announcing results of Phase I Combretastatin A4 phosphate trials trials in solid tumors. Results of the trial conducted by researchers at the University of Pennsylvania Cancer Center showed that patients with solid cancerous tumors were able to safely tolerate combretastatin. [4/00]